Distinctive hobnail subtype of papillary thyroid carcinoma: a case series and short review of literature.

Vishal Yadav, Anupam Lahiri, Sunil Pasricha, Vikas Arora, Prerit Sharma, Suchita Chowdhury, A K Dewan
{"title":"Distinctive hobnail subtype of papillary thyroid carcinoma: a case series and short review of literature.","authors":"Vishal Yadav, Anupam Lahiri, Sunil Pasricha, Vikas Arora, Prerit Sharma, Suchita Chowdhury, A K Dewan","doi":"10.1007/s42000-025-00692-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The hobnail subtype of papillary thyroid carcinoma (HSPTC) is a rare and aggressive subtype, comprising 1-2% of all PTC cases. It is characterized by poor prognosis, frequent BRAF and p53 mutations, and a high recurrence rate. Given the limited data on HSPTC, especially in the Indian population, this case series aims to provide valuable insights into its clinical behavior, mutational profile, and treatment outcomes.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted from January 2021 to December 2023. Histological reports were reviewed for cases with ≥ 5% hobnail features. Cases fulfilling these criteria were reviewed for features of high-grade differentiated thyroid carcinoma. Immunohistochemistry was performed to identify BRAF.V600E and p53. Patient demographics, tumor characteristics, and follow-up data were collected. Follow-up included clinical exams, thyroid function tests, thyroglobulin, anti-thyroglobulin antibody levels, and imaging when necessary.</p><p><strong>Results: </strong>Among 600 PTC cases, 4 were identified as HSPTC (0.67% incidence). The median follow-up was 40 months. Mean tumor size of 3.3 cm. 75% showed BRAF and p53 positivity. Lymphovascular invasion (LVI) was present in 50% of patients. Recurrence occurred in two patients, both with LVI, despite receiving radioactive iodine and radiotherapy. The largest tumor (6 cm) did not show lymph node metastasis, while smaller tumors (2.2 cm, 2.3 cm) were metastatic. Higher mitotic rate showed necrosis and lymph nodal metastasis. Neither BRAF nor p53 positivity correlated with thyroglobulin levels.</p><p><strong>Conclusion: </strong>HSPTC exhibits aggressive behavior, particularly in cases with LVI, high mitotic activity and necrosis. BRAF and p53 mutations are common and cause aggressiveness. Early and aggressive management are essential to improve outcomes.</p>","PeriodicalId":520640,"journal":{"name":"Hormones (Athens, Greece)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones (Athens, Greece)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s42000-025-00692-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The hobnail subtype of papillary thyroid carcinoma (HSPTC) is a rare and aggressive subtype, comprising 1-2% of all PTC cases. It is characterized by poor prognosis, frequent BRAF and p53 mutations, and a high recurrence rate. Given the limited data on HSPTC, especially in the Indian population, this case series aims to provide valuable insights into its clinical behavior, mutational profile, and treatment outcomes.

Materials and methods: A retrospective analysis was conducted from January 2021 to December 2023. Histological reports were reviewed for cases with ≥ 5% hobnail features. Cases fulfilling these criteria were reviewed for features of high-grade differentiated thyroid carcinoma. Immunohistochemistry was performed to identify BRAF.V600E and p53. Patient demographics, tumor characteristics, and follow-up data were collected. Follow-up included clinical exams, thyroid function tests, thyroglobulin, anti-thyroglobulin antibody levels, and imaging when necessary.

Results: Among 600 PTC cases, 4 were identified as HSPTC (0.67% incidence). The median follow-up was 40 months. Mean tumor size of 3.3 cm. 75% showed BRAF and p53 positivity. Lymphovascular invasion (LVI) was present in 50% of patients. Recurrence occurred in two patients, both with LVI, despite receiving radioactive iodine and radiotherapy. The largest tumor (6 cm) did not show lymph node metastasis, while smaller tumors (2.2 cm, 2.3 cm) were metastatic. Higher mitotic rate showed necrosis and lymph nodal metastasis. Neither BRAF nor p53 positivity correlated with thyroglobulin levels.

Conclusion: HSPTC exhibits aggressive behavior, particularly in cases with LVI, high mitotic activity and necrosis. BRAF and p53 mutations are common and cause aggressiveness. Early and aggressive management are essential to improve outcomes.

独特的鞋钉亚型甲状腺乳头状癌:一个病例系列和简短的文献回顾。
鞋甲亚型甲状腺乳头状癌(HSPTC)是一种罕见的侵袭性亚型,占所有PTC病例的1-2%。其特点是预后差,BRAF、p53多发突变,复发率高。鉴于HSPTC的数据有限,特别是在印度人群中,本病例系列旨在为其临床行为、突变特征和治疗结果提供有价值的见解。材料与方法:回顾性分析研究时间为2021年1月至2023年12月。对具有≥5%鞋钉特征的病例回顾组织学报告。我们回顾了符合这些标准的高级别分化甲状腺癌的特征。采用免疫组化方法鉴定BRAF。V600E和p53。收集患者人口统计学、肿瘤特征和随访数据。随访包括临床检查、甲状腺功能检查、甲状腺球蛋白、抗甲状腺球蛋白抗体水平,必要时进行影像学检查。结果:600例PTC中,HSPTC 4例(发生率0.67%)。中位随访时间为40个月。平均肿瘤大小3.3 cm。75%的患者BRAF和p53阳性。50%的患者存在淋巴血管侵犯(LVI)。尽管接受了放射性碘和放疗,两例LVI患者仍出现复发。最大的肿瘤(6cm)未见淋巴结转移,较小的肿瘤(2.2 cm、2.3 cm)有转移。有丝分裂率增高,出现坏死和淋巴结转移。BRAF和p53阳性均与甲状腺球蛋白水平无关。结论:HSPTC表现出侵袭性行为,特别是在LVI病例中,有丝分裂活性高,坏死。BRAF和p53突变是常见的,并引起侵袭性。早期和积极的管理对于改善结果至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信